Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

Add To Watchlist

Recent & Breaking News (NDAQ:CPRX)

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

GlobeNewswire March 2, 2022

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

GlobeNewswire February 24, 2022

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

GlobeNewswire February 17, 2022

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

GlobeNewswire February 7, 2022

Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid

GlobeNewswire February 3, 2022

Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst

GlobeNewswire January 28, 2022

Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing

GlobeNewswire January 10, 2022

Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences

GlobeNewswire January 4, 2022

Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan

GlobeNewswire December 6, 2021

Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 15, 2021

Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

GlobeNewswire November 9, 2021

Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021

GlobeNewswire October 25, 2021

Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS

GlobeNewswire September 30, 2021

Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

GlobeNewswire September 17, 2021

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

GlobeNewswire September 10, 2021

Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations

GlobeNewswire August 16, 2021

Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 9, 2021

Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021

GlobeNewswire July 26, 2021

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®

GlobeNewswire July 19, 2021

Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer

GlobeNewswire July 6, 2021